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Summary: Experimental studies suggest that plasma fibronectin may be involved in the cryoprecipitation of
cryoglobulins in essential mixed cryoglobulinaemia; reduced plasma concentrations of the glycoprotein have
been shown in the disease. The present work was undertaken in order to verify this latter finding and to
detect a possible structural alteration of plasma fibronectin as result of enzymatic digestion of the molecule
in vivo. This could, in turn, induce a decreased reactivity of the protein in immunometric assays and a reduced
opsonic activity, which is normally due to the affinity of fibronectin to the Clq component of complement.
Moreover, since a polymorphic variant of fibronectin has been described in plasma during experimental
vascular injury and in patients with autoimmune vascular diseases, the aim of this study was also to verify
the presence of a polymorphism of the glycoprotein in cryoglobulinaemic vasculitis. Twenty seven patients
with essential mixed cryoglobulinaemia and 26 normal subjects were included in the study. Significantly
reduced concentrations of plasma fibronectin, as assessed by ELISA, were found in patients when compared
with controls (231.7 ± 15.3 vs 316.1 ± 16.6 mg/1, P < 0.0002). In contrast, when affinity-purified plasma
fibronectin from 10 patients with essential mixed cryoglobulinaemia and 8 healthy subjects were analysed by
western blotting, employing a panel of five monoclonal antibodies to different regions of the molecule, no
differences were observed between patients and controls, suggesting integrity of the glycoprotein in the disease.
Moreover, plasma fibronectin from cryoglobulinaemic patients and normal subjects bound to solid phase Clq
in a dose-dependent manner with identical efficiency in the two groups, further suggesting that the molecule
is functionally and structurally unaltered in the disease. The production of an abnormally glycosylated form
of fibronectin in patients with essential mixed cryoglobulinaemia also seems to be excluded, as SDS-PAGE
revealed no differences in electrophoretic mobility and apparent molecular weight between fibronectin from
patients and controls. Taken together these data are consistent with the hypothesis that plasma fibronectin
concentrations are actually reduced in essential mixed cryoglobulinaemia possibly by consumption during
cryoprecipitate formation, and that a polymorphic form of the protein is not released into the circulation
during cryoglobulinaemic vasculitis.
Introduction -S. aureus, collagen, DNA, cells and fibronectin itself;
Fibronectins are high-molecular-mass glycoproteins consequently it plays a central role in several biologic
present in the soluble form in plasma and in insoluble phenomena (2 — 4). Experimental studies have shown
form in the extracellular matrix and basement mem- that fibronectin may be involved in some immune
branes (1). The fibronectin molecule is composed of functions. It has been demonstrated that plasma fi-
multiple globular domains capable of distinct inter- bronectin, mainly produced by hepatocytes (5), acts
actions with other biological structures including fi- as a non-specific opsonin for particulate materials
brin, heparin, plasma transglutaminase (factor XHIa), and microaggregates present in the circulation by
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enhancing their clearance by the reticuloendothelial
system (6 — 10). It has also been suggested that this
glycoprotein may play a role in reticuloendothelial
clearance of circulating immune-complexes primarily
by binding, through its collagen binding domain, to
the Clq component of complement (11 — 13).
Essential mixed cryoglobulinaemia is a disorder char-
acterized by widespread vasculitis and multiple organ
involvement mainly due to the deposition in small
vessels and tissues of circulating cold-insoluble im-
mune-complexes (cryoglobulins) composed of mono-
clonal IgM with rheumatoid-factor activity bound to
polyclonal IgG (14—16). Experimental studies by us
and others have shown that plasma fibronectin may
be associated with cryoglobulins and that it may par-
ticipate in cryoprecipitate formation (17 — 19). We
also recently demonstrated that immunoenzymati-
cally measured plasma fibronectin concentrations are
reduced in patients with essential mixed cryoglobuli-
naemia suggesting that an impairment in plasma op-
sonic activity may be a feature of the disease and can
therefore contribute to the abnormal persistence of
cold-insoluble complexes in the circulation and to
tissue damage (19,20). However the possibility cannot
be excluded that the reduced plasma fibronectin con-
centrations detected in cryoglobulinaemic patients are
the result of an enzymatic cleavage of the molecule
in vivo with loss of fragments essential for immuno-
logic reactivity in the ELISA assays. This hypothesis
seems to be supported by the demonstration by our
group of increased concentrations of plasma tissue
plasminogen activator and thrombin-antithrombin III
complexes in these patients as a consequence of en-
dothelial damage (20), suggesting that the fibronectin
molecule is digested by plasmin produced by activa-
tion of the fibrinolytic pathway and/or by thrombin
formed during the activation of the coagulation cas-
cade (21-23).
Many reports on the molecular biology of fibronectin
have demonstrated that, in different cell systems, a
single fibronectin gene can give rise, by alternative
splicing of the primary transcript, to several different
mRNAs which in turn generate a family of different
fibronectin molecules characterized by the differential
expression of the number of homologous repeats
within the functional domains (24 — 29). A fibronectin
molecule containing an extra type III domain (EDI +
FN), absent in hepatocytes but present in endothelium
and platelets, has been characterized (29 — 32), and
has been detected in plasma during experimental
blood vessel injury (30, 33) and in patients with active
collagen vascular disorders (34). A polymorphism of
plasma fibronectin associated to essential mixed cryo-
globulinaemia has not so far been described. In the
present study we measured plasma fibronectin con-
centrations in a larger series of patients with essential
mixed cryoglobulinaemia and we used an analytical
approach which employed a panel of five monoclonal
antibodies to different functional domains of fibro-
nectin molecule and the western blot technique to
detect possible structural abnormalities of the glyco-
protein in this condition. Plasma fibronectin binding




Twenty seven patients (13 males and 14 females), aged 30 to 72
years (mean 55.2) and 26 normal subjects of comparable age
(35 — 67 years, mean 53) and sex distribution (12 males and 14
females) were included in the study. The diagnosis of essential
mixed cryoglobulinaemia was made after exclusion of under-
lying infectious, neoplastic, and systemic disorders. Quantita-
tion and characterization of the cryoprecipitate were carried
out as previously described (35). Mean cryocrit value was 15.2
±4.3% and the cryoglobulin composition was IgG-IgMk
(monoclonal rheumatoid factor) in all cases. According to clin-
ical chemical analyses, none of the patients showed any indi-
cations of hepatic failure. Nine patients were undergoing low-
dose steroid therapy (prednisone 10—20 mg/day) at the time
of the study. Some clinical and laboratory features of patients
studied are shown in table 1.
Plasma samples
Fasting blood samples were drawn from patients and controls,
after obtaining informed consent, into prewarmed plastic tubes
containing 38 g/1 sodium citrate; samples were immediately
centrifuged at 2400 g for 15 min at 37 °C, and the plasma was
collected and immediately deep frozen until assayed, or purified
by chromatography. Before use samples were thawed at 37 °C
to avoid fibrin formation.
Plasma fibronectin determination
This was performed with an enzyme-linked immunosorbent
assay (ELISA) as previously described (19) which employed a
goat IgG to human fibronectin (Jackson Laboratories) as first
antibody (coating antibody) and a peroxidase-conjugated goat
IgG to human fibronectin as second antibody. The standard
curve was prepared using both commercially available purified
fibronectin (Behring) and affinity-purified fibronectin prepared
in our laboratory from normal human plasma (see below).
Each immunoassay included patients and controls in each run.
The plates were read in a multichannel photometer (Titertek
Multiscan MC, Flow Laboratories) interfaced to an Apple He
microcomputer and the results expressed in milligrams per litre.
Between-day coefficient of variation was below 5% in both
patients with essential mixed cryoglobulinaemia and controls.
Plasma fibronectin purification
Plasma fibronectin from 10 patients (5 men and 5 women) and
8 normal subjects (5 men and 3 women) was purified using
gelatin affinity chromatography according to the method de-
scribed by Engvall & Rouslahti (36). To prepare the gelatin
affinity columns, gelatin (type I from porcine skin, Sigma) was
coupled to CNBr-activated Sepharose 4B (Pharmacia) accord-
ing to the procedure provided by the manufacturer. Citrated
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Tab. 1. Some routine clinical and laboratory findings of patients with essential mixed cryoglobulinaemia. Complement levels were
measured by radial immunodiffusion and values are expressed as % of reference normal plasma. Rheumatoid factor (RF)
was assessed by ELISA and values are expressed as mg/1. Cryocrit is expressed as %. Reference values of our laboratory
are 65-140% for C3, 43-156% for C4, 64-120% for Clq and below 8 mg/1 for rheumatoid factor.























































































plasma (25 ml) was applied to the column and fibronectin was
then eluted with 8 mol/1 urea in 50 mmol/1 Tris-buffer, pH 7.5.
The entire procedure was performed at 37 °C. Protein was
determined by absorbance at 280 nm, using as reference a
standard curve prepared with commercially available purified
fibronectin (Behring) at various dilutions. Plasma fibronectin
recovery averaged 1.2 and 1.8 mg of protein in patients and
controls respectively. Purity of plasma fibronectin preparations
was assessed by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) (see results).
SDS-polyacrylamide gel electrophoresis (SDS-
PAGE)
SDS-PAGE of purified preparations was carried out under
reducing conditions using 5% acrylamide slab gels (37). The
samples were reduced by incubation with 20 g/1 2-mercapto-
ethanol at 56 °C for 1 hour. Preliminary experiments were
carried out by running purified plasma fibronectin preparations
with reduced standard plasma fibronectin (Behring) (MT
220000), myosin (Mr 200000), -galactosidase (Mr 116250),
phosphorylase a (Mr 93 000), human serum albumin (Mr 68 000)
and ovalbumin (Mr 45 000) as molecular mass markers (Biorad);
gel slabs were stained with Coomassie blue.
Western blotting
Proteins were transferred electrophoretically from polyacrylam-
ide gel onto nitrocellulose paper as described by Towbin et al.
(38). The blots were soaked in Tris-NaCl pH 7.5 + 50 g/1
bovine serum albumin overnight at room temperature, rinsed
with phosphate buffered saline, containing 10 g/1 bovine serum
albumin and incubated with a 1 :1000 dilution of the appro-
priate monoclonal antibody for 2 hours at 37 °C. After three
extensive washes in phosphate buffered saline containing 10 g/1
bovine serum albumin the blots were incubated with a 1 :400
dilution of peroxidase-conjugated anti-mouse Ig antibody
(Dako) for 1 hour at 37 °C and after three more washes the
substrate (500 g/1 4-chloro-l-naphthol in H2O2) was added and
sufficient time allowed for the reaction to occur.
Monoclonal antibodies
Five commercially available monoclonal antibodies (Mallinck-
rodt), each recognizing different human fibronectin epitopes,
were used (39—43). Binding specificities and clone of origin of
the antibodies employed are shown in table 2.
Plasma fibronectin binding to Clq
The binding of purified fibronectin from patients and controls
to Clq was assessed by ELISA using a modification of the
method previously described by Baatrup & Svehag (13). Briefly,
the wells of microtitre plates (Dynatech) were coated overnight
with a 4 mg/1 solution of Clq (Sigma) in phosphate buffered
saline. The plates were then washed three times with phosphate
buffered saline Tween and blocked with phosphate buffered
saline containing 1 g/1 Tween and 0.5 g/1 human serum albumin
for 2 hours at room temperature. Purified plasma fibronectin
samples were serially diluted in phosphate buffered saline, and
100 μΐ of the diluted samples and standards were added to each
Clq-coated well in duplicate. The plates were then incubated
for 2 hours at 37 °C. The standard fibronectin curve was ob-
tained by using purified fibronectin from a commercial source
Tab. 2. Monoclonal antibodies employed in plasma fibronectin molecule mapping by western blotting. The specificity of the
antibodies, i. e. the region of fibronectin recognized, and the clone from which the different monoclonal antibodies were





























central portion of fibronectin monomer
Mr 11 000 cell adhesive fragment
pepsin cleavage site at N-terminal
of the Afr 11 000 cell adhesive fragment
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(Behring). After three more washes 100 μΐ of a peroxidase-
conjugated goat anti-human fibronectin IgG (Jackson Labo-
ratories) diluted 1 : 400 in phosphate buffered saline were added
to each well. The plates were then incubated at 37 °C for 1
hour and washed. Finally the substrate (500 g/l ABTS in H2O2,
KPL Laboratories) was added and sufficient time allowed for
the reaction to occur. The plates were then read in a Titertek
Multiscan MC photometer (Flow Laboratories) interfaced to
an Apple lie microcomputer.
Statistical analysis
Wilcoxorfs rank sum test was applied when appropriate, using
an IBM personal computer and a suitable statistical package
(Epistat).
Results
The results of plasma fibronectin assay in patients
with essential mixed cryoglobulinaemia and in con-
trols are shown in figure 1. It can be seen that plasma
fibronectin concentrations were significantly lower in
the patients than in normal subjects (231.7 ± 15.3 vs
316.1 ± 16.6 mg/1, P < 0.0002), confirming our pre-
















Fig. 1. Plasma fibronectin concentrations in patients with es-
sential mixed cryoglobulinaemia (left) and in healthy
subjects (right), ρ = 0.0002
In agreement with previously reported observations
(36, 44), SDS-PAGE of reduced plasma fibronection
from both patients and controls showed a single poly-
peptide band with a relative molecular mass of about
Mr 250 000, indicating size homogeneity of the puri-
fied protein. No protein other than fibronectin was
visualized by Coomassie blue staining in the purified
preparations. Electrophoretic mobility of plasma fi-
bronectin bands was identical in the two groups of
subjects.
All purified plasma fibronectin samples from cryo-
globulinaemic patients and control subjects stained
with CBP, CBX, MM and CT monoclonal antibodies
by western blot analysis (fig. 2). As can be seen,
staining intensity and shape of the bands were com-
parable in the two groups, and no difference of reac-
tivity was observed when commercially available
plasma fibronectin (Behring) was tested. None of the
plasma fibronectin preparations could be stained with
the monoclonal antibody against N-terminal region
of the molecule (NT), suggesting loss of the N-ter-
minal peptide fragment during the Chromatographie
procedure.
1 2 3 4 5 6 7 8 9 K> 11 12 13 14 15 16 17 18
Fig. 2. Western blotting analysis of purified plasma fibronectin
from normal subjects (lanes 1—4 and 15 — 18) and from
patients with essential mixed cryoglobulinaemia (lanes
5 — 14) using 784A2A6 monoclonal antibody to the cell
binding peptide of the fibronectin molecule.
The binding of plasma fibronectin from patients with
essential mixed cryoglobulinaemia and controls to
solid phase Clq is shown in figure 3. Purified fibro-
nectin, tested at progressively halved dilutions in
phosphate buffered saline at concentrations ranging
from 4 to 500 mg/1, was found to bind in Clq coated
wells in a dose-dependent fashion, thus confirming
previously reported observations (11, 13). As can be
observed, no significant difference in binding effi-
ciency to Clq was observed between plasma fibro-
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Fig. 3. Binding of purified plasma fibronectin from patients
with essential mixed cryoglobulinaemia (A) and from
healthy subjects (·) to solid phase Clq. Data are ex-
pressed as mean + SEM.
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Discussion
In the present work we confirm that plasma fibro-
nectin is significantly decreased in patients with es-
sential mixed cryoglobulinaemia when compared with
normal controls. In contrast, when western blotting
was used to map the purified molecule obtained from
both groups by a panel of five monoclonal antibodies
to different fibronectin epitopes, no differences were
revealed between fibronectin from patients and nor-
mal subjects, suggesting that the glycoprotein struc-
ture is unaltered in the disease. We previously showed
that fibronectin is constantly present in cryoprecipi-
tate from cryoglobulinaemic patients (19), suggesting
that the molecule could be actively involved in the in
vivo formation of the cryoprecipitate. This, in turn,
could result in the consumption of the glycoprotein,
leading to a reduction of its plasma concentration.
The alternative hypothesis of an enzymatic cleavage
of fibronectin by plasmin and/or thrombin produced
in vivo in patients with essential mixed cryoglobulin-
aemia with loss of immunoreactive fragments, as sug-
gested by recent data from our group (20), seems to
be excluded on the basis of the western blotting results
of the present study which demonstrate that plasma
fibronectin concentrations are actually reduced in the
disease.
It has been shown experimentally that in different cell
systems different fibronectin mRNAs originate by
alternative splicing of a common precursor RNA.
These, in turn, give rise to a family of fibronectin
polymorphic variants differing in their primary se-
quences (24 — 28). One of these polymorphic mole-
cules containing an extra type III domain, EDl-f
FN, was detected in endothelium and platelets (29 —
32) and was shown to be released into the circulation
during experimental vascular injury (30, 33) and to
be increased in the plasma of patients with vasculitis
associated with connective tissue disorders (34). In
the same patients, an increased plasma concentration
of total fibronectin was also reported. These data
seem to contradict those found in the present work,
since our experimental approach demonstrated no
polymorphism of the glycoprotein in association with
cryoglobulinaemic vasculitis, and significantly re-
duced rather than increased concentrations of total
fibronectin were demonstrated in our patients. On the
other hand, an impairment of the hepatic biosynthesis
of plasma fibronectin, which can be advocated as a
possible cause of the reduced plasma concentrations
of the glycoprotein in essential mixed cryoglobulinae-
mia, may be ruled out by the normality of the liver
function results constantly observed in our series.
We also demonstrated that plasma fibronectin binds
to solid phase Clq in a dose-dependent manner, thus
confirming previously reported observations (11, 13).
Recently it was also clearly shown that the glycopro-
tein has a strong affinity for Clq bound to fluid phase
immune-complexes (13, 45). This interaction, me-
diated by the Mr 50000 gelatin-binding domain of
the molecule (46), may play a key role in immune-
complex clearance by the reticuloendothelial system
(12), which also critically depends on the interaction
of the cell-binding domain of fibronectin with mac-
rophages (42). On the other hand, fibronectin affinity
to immune complex-associated Clq also seems to be
important in mediating cryoprecipitation of cryoglob-
ulins (11). Our data demonstrate that both domains
are present in fibronectin purified from patients with
essential mixed cryoglobulinaemia, suggesting that en-
zymatic cleavage of the molecule has not occurred at
these sites and that opsonic function is retained by
the glycoprotein in the disease. The demonstration
that plasma fibronectin from cryoglobulinaemic pa-
tients binds to Clq with the same efficiency as plasma
fibronectin purified from controls further supports
the evidence of structural as well as functional integ-
rity of the molecule as far as opsonic properties are
concerned. However the integrity of the gelatin-bind-
ing domain of the plasma protein in essential mixed
cryoglobulinaemia suggests that the molecule might
also efficiently mediate cryoprecipitation of cold in-
soluble complexes, thereby playing a role in vascular
and tissue damage.
Finally, our study also seems to exclude the possibility
that an abnormally glycosylated fibronectin molecule,
which has been reported in different cell systems and
body fluids (47, 48), is produced and released in
essential mixed cryoglobulinaemia; using SDS-PAGE,
no differences in electrophoretic mobility or apparent
molecular mass were observed between plasma fibro-
nectin from patients and controls. However, the pos-
sibility cannot be excluded that subtle alterations are
present in regions of the polypeptide chain not ex-
plored by the monoclonal antibodies employed in this
study. Further work is necessary to clarify these issues.
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